Lupin launches Oral Contraceptive Daysee Tablets in the US market

15 Apr 2013 Evaluate

Lupin’s subsidiary - Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Daysee Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.15 mg/0.03 mg and Ethinyl Estradiol Tablets, USP, 0.01 mg) from the United States Food and Drugs Administration (US FDA) to market a generic version of Teva Branded Pharm.’s Seasonique Tablets.

Lupin’s Daysee Tablets is indicated for use by women to prevent pregnancy. The total sales for Branded and generic sales for the product stood at $161 million (IMS MAT Dec 2012). Lupin has already commenced shipping the product.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Lupin Share Price

2109.20 28.20 (1.36%)
31-Dec-2025 13:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1271.05
Cipla 1506.25
Zydus Lifesciences 913.60
Lupin 2109.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×